Upcoming market catalysts for the first quarter of 2025 include the anticipated FDA decisions on the approval of mirdametinib for neurofibromatosis type 1-associated plexiform neurofibromas, rivoceranib in combination with camrelizumab for hepatocellular carcinoma and etripamil nasal spray (Cardamyst) for paroxysmal supraventricular tachycardia (PSVT).
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
The author declares no competing interests.